查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830992

多囊性卵巢症候群（PCOS）治疗市场

Polycystic Ovarian Syndrome (PCOS) Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

多囊性卵巢症候群 (PCOS) 治疗市场预测有助于利害关係人制定成长策略。预计该市场规模将从 2024 年的 39.8 亿美元增至 2031 年的 52.6 亿美元，2025 年至 2031 年的复合年增长率估计为 5.4%。全球 PCOS 盛行率的上升，以及 PCOS 治疗医疗支出的显着增长，是推动多囊性卵巢症候群 (PCOS) 治疗市场成长的关键因素。例如，美国约有 600 万名女性患有 PCOS，这是一种常见的荷尔蒙失调疾病，会增加子宫内膜癌、高血压、2 型糖尿病、不孕症和中风等各种健康问题的风险。此外，美国内分泌学会预测，PCOS 是育龄女性中最常见的荷尔蒙失调疾病，2020 年其诊断和治疗将在美国产生 80 亿美元的全国性费用。

预计在预测期内，创新疗法的发展将为多囊性卵巢症候群 (PCOS) 治疗市场带来新的趋势。

成长动力：全球女性多囊性卵巢症候群 (PCOS) 发生率上升推动多囊性卵巢症候群 (PCOS) 治疗市场的成长多囊性卵巢症候群 (PCOS) 是一种影响女性的广泛多因子内分泌疾病。世界卫生组织 (WHO) 估计，PCOS 影响约 8-13% 的育龄妇女。它是导致无排卵的主要原因，也是全球不孕症的重要因素。此外，约 70% 的多囊性卵巢症候群女性仍未被诊断出来。不健康饮食和某些环境影响等因素会导致 PCOS 的发病。肥胖是重要的风险因素，因为超重会破坏荷尔蒙平衡和胰岛素敏感性，从而导致病情发展。随着全球肥胖危机的加剧，越来越多的女性面临 PCOS 的风险。根据世界肥胖联合会发布的《2022年世界肥胖地图集》，到2030年，全球将有超过10亿人受到肥胖的影响，其中包括五分之一的女性。

此外，多囊性卵巢症候群 (PCOS) 发病率的不断上升也导致了对有效治疗方案的需求日益增长。目前已有多种药物和非药物疗法可用于调节荷尔蒙水平、增强胰岛素敏感性以及解决其他与 PCOS 相关的潜在问题。因此，全球女性 PCOS 盛行率的不断上升是多囊性卵巢症候群 (PCOS) 治疗市场成长的重要驱动力。

限制：FDA 批准的 PCOS 药物供应有限，阻碍了多囊性卵巢症候群 (PCOS) 治疗市场的发展。 FDA 批准的专门用于治疗与多囊性卵巢症候群 (PCOS) 相关的复杂症状和荷尔蒙失衡的药物供应有限。儘管 PCOS 盛行率高，并且对女性健康、生育能力和生活品质造成巨大影响，但 FDA 批准的治疗这种疾病的药物选择相对较少（通常是超说明书用药）。 FDA 批准药物的稀缺性给寻求有效、循证 PCOS 治疗的医疗保健提供者和患者带来了挑战。虽然超说明书用药某些药物（如口服避孕药、胰岛素增敏剂和抗雄性激素药物）在治疗 PCOS 症状方面很常见，但缺乏专门的治疗方法限制了综合治疗方案。因此，FDA 批准的专门针对 PCOS 的药物有限阻碍了多囊性卵巢症候群 (PCOS) 治疗市场的成长。

策略洞察报告细分和范围：透过检查以下细分市场对多囊性卵巢症候群 (PCOS) 治疗市场进行分析：产品和配销通路。

依产品划分，多囊性卵巢症候群 (PCOS) 治疗市场分为克罗米芬柠檬酸盐、二甲双胍、吡格列酮、口服避孕药等。二甲双胍在 2023 年占据最大市场份额，而克罗米芬柠檬酸盐预计在预测期内将呈现最高的复合年增长率。

从配销通路来看，多囊性卵巢症候群 (PCOS) 治疗市场分为医院药房、零售药房和线上药房。 2023 年，医院药局占据多囊性卵巢症候群 (PCOS) 治疗市场的最大份额，预计在预测期内将实现最高的复合年增长率。

区域分析：从地理上讲，多囊性卵巢症候群 (PCOS) 治疗市场报告的范围包括北美、欧洲、亚太地区、南美和中美以及中东和非洲。 2023 年，北美占据了最大的市场份额。先进医疗器材技术的日益普及、PCOS 盛行率的上升以及主要参与者的持续产品创新，促进了北美多囊性卵巢症候群 (PCOS) 治疗市场的成长。根据美国卫生与公共服务部的数据，PCOS 是美国女性不孕症的常见原因，影响约 6% 至 12%（约 500 万）的育龄妇女。 2023 年 7 月发表在《美国妇产科杂誌》上的一项研究报告称，美国每年每 10,000 人中有 42.5 例 PCOS 发病率。此外，该国各组织致力于全面评估、提高意识并专注于与 PCOS 相关的研究。例如，加州大学旧金山分校生殖健康中心积极参与研究，以了解多囊性卵巢症候群 (PCOS) 的病因。因此，PCOS 的高盛行率以及专注于研究和提高认知度的机构的存在，推动了多囊性卵巢症候群 (PCOS) 治疗市场的成长。

多囊性卵巢症候群 (PCOS) 治疗市场报告范围产业发展与未来机会：正如公司新闻稿所报导的，多囊性卵巢症候群 (PCOS) 治疗市场主要参与者的几项策略发展重点如下：

2023年4月，Celmatix启动了一项新的PCOS药物项目，推出了其最新的针对中枢神经系统(CNS)外褪黑激素受体的治疗方案。该治疗方法旨在填补针对各种女性健康问题的有效一线疗法的巨大市场空白，这些问题首先是PCOS，并可能扩展到子宫内膜异位症和更年期症状。 2022年1月，Celmatix公司宣布与Evotec公司为期五年的多标靶合作取得了里程碑式的成果。 Evotec 和拜耳公司达成了一项里程碑，将以 Celmatix 确定的新药物标靶为重点的 PCOS 药物计划推进到命中确定阶段。竞争格局与关键公司：多囊性卵巢症候群 (PCOS) 治疗市场报告中介绍的知名公司包括赛诺菲公司、默克公司、诺华公司、迈兰公司、武田製药有限公司、雅培公司、梯瓦製药公司、Salix Pharmaceuticals Inc、阿斯利康公司和辉瑞公司。这些公司致力于开发新技术、改进现有产品并扩大其地理覆盖范围，以满足日益增长的全球消费者需求。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：多囊性卵巢症候群（PCOS）治疗市场格局

  • 概述
  • PEST分析

第五章：多囊性卵巢症候群（PCOS）治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：多囊性卵巢症候群（PCOS）治疗市场 - 全球市场分析

  • 多囊性卵巢症候群（PCOS）治疗－全球市场概览
  • 多囊性卵巢症候群 (PCOS) 治疗 - 全球市场及 2031 年预测

第七章：多囊性卵巢症候群（PCOS）治疗市场-收入分析-按产品，2021-2031

  • 概述
  • 克罗米芬柠檬酸盐
  • 二甲双胍
  • 吡格列酮
  • 口服避孕药
  • 其他的

第 8 章：多囊性卵巢症候群 (PCOS) 治疗市场 - 收入分析 - 按配销通路，2021-2031 年

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第九章：多囊性卵巢症候群（PCOS）治疗市场－收入分析，2021-2031－地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 12 章：多囊性卵巢症候群 (PCOS) 治疗市场 - 主要公司简介

  • Sanofi SA
  • Merck KGaA
  • Novartis
  • Mylan
  • Takeda Pharmaceutical Company Ltd
  • Abbott
  • Teva Pharmaceuticals
  • Salix Pharmaceuticals
  • AstraZeneca
  • Pfizer Inc

第 13 章：附录

简介目录
Product Code: TIPRE00004072

The forecast for the polycystic ovarian syndrome (PCOS) treatment market assists stakeholders in formulating their growth strategies. The market is expected to expand from US$ 3.98 billion in 2024 to US$ 5.26 billion by 2031, with an estimated CAGR of 5.4% from 2025 to 2031.The rising global prevalence of PCOS, along with a notable increase in healthcare expenditures on PCOS treatments, are key factors driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. For example, around 6 million women in the US are affected by PCOS, a prevalent hormonal disorder that elevates the risk of various health issues, including endometrial cancer, hypertension, type 2 diabetes, infertility, and stroke. Additionally, the Endocrine Society projects that the diagnosis and treatment of PCOS, the most common hormonal disorder among women of reproductive age, will incur a national cost of US$ 8 billion in 2020.

The development of innovative therapeutics is expected to introduce new trends in the polycystic ovarian syndrome (PCOS) treatment market during the forecast period.

Growth Drivers:Rising Global Incidence of PCOS Among Women Fuels Growth in the Polycystic Ovary Syndrome (PCOS) Treatment Market

Polycystic ovary syndrome (PCOS) is a widespread multifactorial endocrine disorder affecting women. The World Health Organization (WHO) estimates that PCOS impacts approximately 8-13% of women of reproductive age. It is the leading cause of anovulation and a significant contributor to infertility worldwide. Furthermore, about 70% of women with PCOS remain undiagnosed. Factors such as unhealthy diets and certain environmental influences can lead to the onset of PCOS. Obesity is a significant risk factor, as excess body weight can disrupt hormonal balance and insulin sensitivity, contributing to the condition's development. With the global obesity crisis escalating, more women are at risk of developing PCOS. According to the World Obesity Federation's 2022 World Obesity Atlas, over one billion people globally will be affected by obesity by 2030, including one in five women.

Moreover, the increasing incidence of PCOS has resulted in a heightened demand for effective treatment options. A variety of pharmaceutical and non-pharmaceutical treatments are available to help regulate hormone levels, enhance insulin sensitivity, and address other underlying issues related to PCOS. Therefore, the growing prevalence of PCOS among women worldwide is a significant driver of the polycystic ovarian syndrome (PCOS) treatment market's growth.

Restraint:Limited Availability of FDA-Approved Medications for PCOS Impedes the Polycystic Ovarian Syndrome (PCOS) Treatment Market

The availability of FDA-approved medications specifically designed to treat the complex symptoms and hormonal imbalances associated with polycystic ovary syndrome (PCOS) is limited. Despite the high prevalence of PCOS and its considerable impact on women's health, fertility, and quality of life, there are relatively few FDA-approved pharmaceutical options (often off-label) for treating this condition. This scarcity of FDA-approved medications poses challenges for healthcare providers and patients seeking effective, evidence-based treatments for PCOS. While off-label use of certain medications, such as oral contraceptives, insulin-sensitizing agents, and anti-androgens, is common in managing PCOS symptoms, the lack of dedicated therapies restricts comprehensive treatment options. Consequently, the limited availability of FDA-approved medications specifically for PCOS hinders the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Strategic Insights

Report Segmentation and Scope:The analysis of the polycystic ovarian syndrome (PCOS) treatment market has been conducted by examining the following segments: product and distribution channel.

By product, the polycystic ovarian syndrome (PCOS) treatment market is divided into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment accounted for the largest market share in 2023, while the clomiphene citrate segment is expected to exhibit the highest CAGR during the forecast period.

In terms of distribution channel, the polycystic ovarian syndrome (PCOS) treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the polycystic ovarian syndrome (PCOS) treatment market in 2023 and is projected to register the highest CAGR during the forecast period.

Regional Analysis:Geographically, the scope of the polycystic ovarian syndrome (PCOS) treatment market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held the largest market share. The increasing adoption of advanced medical device technologies, the rising prevalence of PCOS, and ongoing product innovations by key players are contributing to the growth of the polycystic ovarian syndrome (PCOS) treatment market in North America. According to the US Department of Health & Human Services, PCOS is a common cause of female infertility in the US, affecting approximately 6% to 12% (around 5 million) of women of reproductive age. A study published in July 2023 in the American Journal of Obstetrics and Gynecology reported an incidence rate of 42.5 cases of PCOS per 10,000 people annually in the US. Additionally, various organizations in the country are dedicated to comprehensive evaluation, raising awareness, and focusing on research related to PCOS. For instance, the UCSF Center for Reproductive Health is actively involved in research to understand the causes of PCOS. Thus, the high prevalence of PCOS and the presence of organizations focused on research and awareness support the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Report Scope

Industry Developments and Future Opportunities:Several strategic developments by leading players in the polycystic ovarian syndrome (PCOS) treatment market, as reported in company press releases, are highlighted below:

In April 2023, Celmatix launched a new PCOS drug program, introducing its latest therapeutic initiative targeting melatonin receptors outside the central nervous system (CNS). This therapeutic approach aims to fill a significant market gap for effective first-line therapies for various women's health issues, starting with PCOS and potentially extending to endometriosis and menopausal symptoms.

In January 2022, Celmatix Inc. announced a milestone achievement in its five-year, multi-target collaboration with Evotec. Evotec and Bayer AG reached a milestone to advance a PCOS drug program focused on a novel drug target identified by Celmatix into the hit identification phase.

Competitive Landscape and Key Companies:Prominent companies profiled in the polycystic ovarian syndrome (PCOS) treatment market report include Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc. These companies are dedicated to developing new technologies, enhancing existing products, and expanding their geographic reach to meet the increasing global consumer demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Polycystic Ovarian Syndrome (PCOS) Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Global Market Analysis

  • 6.1 Polycystic Ovarian Syndrome (PCOS) Treatment - Global Market Overview
  • 6.2 Polycystic Ovarian Syndrome (PCOS) Treatment - Global Market and Forecast to 2031

7. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Revenue Analysis (USD Million) - By Product, 2021-2031

  • 7.1 Overview
  • 7.2 Clomiphene Citrate
  • 7.3 Metformin
  • 7.4 Pioglitazone
  • 7.5 Oral Contraceptives
  • 7.6 Others

8. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 8.1 Overview
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    • 9.1.2 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts to 2031
    • 9.1.3 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts and Analysis - By Product
    • 9.1.4 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 9.1.5 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market
        • 9.1.5.1.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Product
        • 9.1.5.1.2 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Distribution Channel
      • 9.1.5.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market
        • 9.1.5.2.1 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Product
        • 9.1.5.2.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Distribution Channel
      • 9.1.5.3 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market
        • 9.1.5.3.1 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Product
        • 9.1.5.3.2 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Distribution Channel
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Key Company Profiles

  • 12.1 Sanofi SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Merck KGaA
  • 12.3 Novartis
  • 12.4 Mylan
  • 12.5 Takeda Pharmaceutical Company Ltd
  • 12.6 Abbott
  • 12.7 Teva Pharmaceuticals
  • 12.8 Salix Pharmaceuticals
  • 12.9 AstraZeneca
  • 12.10 Pfizer Inc

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud